Last reviewed · How we verify
BMS-986213
At a glance
| Generic name | BMS-986213 |
|---|---|
| Sponsor | Bristol-Myers Squibb |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Pan Tumor Rollover Study (PHASE2)
- A Randomized Phase 2 Trial of Nivolumab, Relatlimab Plus Ipilimumab vs. Nivolumab Plus Ipilimumab in First-line Advanced Renal Cell Carcinoma (RCC) (PHASE2)
- A Study To Assess the Safety, and Tolerability of Nivolumab + Relatlimab Fixed-Dose Combination (FDC) In Untreated, Unresectable or Metastatic Melanoma Participants In India (PHASE4)
- A Study of BMS-986482 Alone or as Combination Therapy in Participants With Advanced Solid Tumors (PHASE1, PHASE2)
- Phase II Study of Nivolumab in Combination With Relatlimab in Patients With Active Melanoma Brain Metastases (PHASE2)
- A Study to Assess Adjuvant Immunotherapy With Nivolumab Plus Relatlimab Versus Nivolumab Alone After Complete Resection of Stage III-IV Melanoma (PHASE3)
- An Investigational Immuno-therapy Study to Assess the Safety, Tolerability and Effectiveness of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid Tumors (PHASE1, PHASE2)
- Interleukin-6 Receptor Inhibitor Sarilumab in Combination With Ipilimumab, Nivolumab and Relatlimab in Patients With Unresectable Stage III or Stage IV Melanoma (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- BMS-986213 CI brief — competitive landscape report
- BMS-986213 updates RSS · CI watch RSS
- Bristol-Myers Squibb portfolio CI